Nivolumab-Associated Acute Liver Failure: A Report of Two Cases
Abstract
Nivolumab is utilized for treating multiple advanced malignancies, with a fraction of patients experiencing immune-related side effects due to immune enhancement. Severe immune-related hepatic injury from nivolumab is very rare and typically responds well to corticosteroids. Here, we present two cases illustrating this phenomenon: one involving extensive-stage small cell carcinoma of the lung with disseminated liver and bone metastasis where nivolumab was administered as a fourth-line treatment and another involving uveal melanoma with liver metastasis where nivolumab was given as first-line palliative systemic therapy. Both cases demonstrated accelerated hepatic deterioration and unresponsiveness to timely steroid administration following the first cycle of nivolumab administration in 3-11 days.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Polyomavirus and related diseases
Ocular Oncology and Treatments
Publication details
- Journal / source
- Cureus
- Publisher
- Springer Science and Business Media LLC
- Volume
- 18
- Issue
- 4
- Pages
- e106589–e106589
- Publication date
- 7 April 2026
- Language
- EN